Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...
Yahoo Finance

Here's Why Investors Should Invest in Arcturus Stock Now

Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...
Today

New COVID variant Arcturus XBB.1.16 may cause unusual symptoms in kids, docs say

The Arcturus COVID-19 variant has arrived in the United States and is here to stay, according to experts. While it's unclear whether it will drive a summer surge, some doctors are warning that the ...
Morningstar

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...
Hosted on MSN

Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic ...

Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary ...
Hosted on MSN

Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
FierceBiotech

Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources'

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...
People

New COVID-19 Strain Arcturus May Cause Pink Eye, L.A. County Health Officials Say

Los Angeles County Department of Public Health confirmed three cases of the Arcturus strain with "observational data" suggesting that those infected may be likely to experience pink eye Alexis Jones ...
Los Angeles Times

New coronavirus subvariant Arcturus is now in L.A. Is there reason to worry?

Los Angeles County has identified its first cases of an emerging Omicron coronavirus subvariant dubbed Arcturus, a strain global health authorities are watching closely as it has been linked to an ...
USA Today

A new COVID variant called Arcturus is linked to pink eye. Here's what you need to know.

About 1 in 10 cases of COVID-19 nationwide is caused by an emerging coronavirus strain, XBB.1.16. The World Health Organization has elevated this strain of omicron to one of two "circulating variants ...